Literature DB >> 29371416

Bardoxolone-the Phoenix?

Robert D Toto1,2.   

Abstract

Entities:  

Keywords:  Alport-s syndrome; Bardoxolone; Chronic inflammation; chronic kidney disease

Mesh：

Substances：

Year:  2018        PMID： 29371416      PMCID： PMC5791054          DOI： 10.1681/ASN.2017121317

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  12 in total

1.  Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

Authors:  Dick de Zeeuw; Tadao Akizawa; Paul Audhya; George L Bakris; Melanie Chin; Heidi Christ-Schmidt; Angie Goldsberry; Mark Houser; Melissa Krauth; Hiddo J Lambers Heerspink; John J McMurray; Colin J Meyer; Hans-Henrik Parving; Giuseppe Remuzzi; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; Janet Wittes; Danielle Wrolstad; Glenn M Chertow
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

2.  Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.

Authors:  Melanie P Chin; George L Bakris; Geoffrey A Block; Glenn M Chertow; Angie Goldsberry; Lesley A Inker; Hiddo J L Heerspink; Megan O'Grady; Pablo E Pergola; Christoph Wanner; David G Warnock; Colin J Meyer
Journal:  Am J Nephrol       Date:  2018-01-18       Impact factor: 3.754

3.  Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.

Authors:  Melanie P Chin; Scott A Reisman; George L Bakris; Megan O'Grady; Peter G Linde; Peter A McCullough; David Packham; Nosratola D Vaziri; Keith W Ward; David G Warnock; Colin J Meyer
Journal:  Am J Nephrol       Date:  2014-06-03       Impact factor: 3.754

4.  Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Authors:  Pablo E Pergola; Philip Raskin; Robert D Toto; Colin J Meyer; J Warren Huff; Eric B Grossman; Melissa Krauth; Stacey Ruiz; Paul Audhya; Heidi Christ-Schmidt; Janet Wittes; David G Warnock
Journal:  N Engl J Med       Date:  2011-06-24       Impact factor: 91.245

5.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

6.  Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity.

Authors:  Melanie Chin; Chun-Yue Ivy Lee; Jen-Chieh Chuang; Ron Bumeister; W Christian Wigley; Stephen T Sonis; Keith W Ward; Colin Meyer
Journal:  Am J Physiol Renal Physiol       Date:  2013-04-17

7.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Akshay S Desai; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Patrick Brunel; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

8.  Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.

Authors:  Melanie P Chin; Danielle Wrolstad; George L Bakris; Glenn M Chertow; Dick de Zeeuw; Angie Goldsberry; Peter G Linde; Peter A McCullough; John J McMurray; Janet Wittes; Colin J Meyer
Journal:  J Card Fail       Date:  2014-10-13       Impact factor: 5.712

9.  The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells.

Authors:  Yanfeng Ding; Rhesa D Stidham; Ron Bumeister; Isaac Trevino; Ali Winters; Marc Sprouse; Min Ding; Deborah A Ferguson; Colin J Meyer; W Christian Wigley; Rong Ma
Journal:  Kidney Int       Date:  2012-12-12       Impact factor: 10.612

10.  The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.

Authors:  Mohammad A Aminzadeh; Scott A Reisman; Nosratola D Vaziri; Mahyar Khazaeli; Jun Yuan; Colin J Meyer
Journal:  Xenobiotica       Date:  2013-11-06       Impact factor: 1.908
View more
  11 in total

Review 1.  The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway.

Authors:  Liam Baird; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2020-06-15       Impact factor: 4.272

2.  Editorial Note: From Both Sides Now.

Authors:  Josephine P Briggs; Thomas H Hostetter
Journal:  J Am Soc Nephrol       Date:  2018-01-25       Impact factor: 10.121

3.  Emerging drugs for treatment of focal segmental glomerulosclerosis.

Authors:  Howard Trachtman
Journal:  Expert Opin Emerg Drugs       Date:  2020-08-12       Impact factor: 4.191

4.  Nrf2 Regulates β-Cell Mass by Suppressing β-Cell Death and Promoting β-Cell Proliferation.

Authors:  Sharon Baumel-Alterzon; Liora S Katz; Gabriel Brill; Clairete Jean-Pierre; Yansui Li; Isabelle Tse; Shyam Biswal; Adolfo Garcia-Ocaña; Donald K Scott
Journal:  Diabetes       Date:  2022-05-01       Impact factor: 9.337

Review 5.  Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).

Authors:  Raymond Vanholder; Steven Van Laecke; Griet Glorieux; Francis Verbeke; Esmeralda Castillo-Rodriguez; Alberto Ortiz
Journal:  Toxins (Basel)       Date:  2018-06-12       Impact factor: 4.546

Review 6.  Eat Your Broccoli: Oxidative Stress, NRF2, and Sulforaphane in Chronic Kidney Disease.

Authors:  Scott E Liebman; Thu H Le
Journal:  Nutrients       Date:  2021-01-18       Impact factor: 5.717

Review 7.  Mitochondria-targeted drugs for diabetic kidney disease.

Authors:  Akira Mima
Journal:  Heliyon       Date:  2022-02-03

Review 8.  Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases.

Authors:  Min-Ji Kim; Jae-Han Jeon
Journal:  Int J Mol Sci       Date:  2022-03-05       Impact factor: 5.923

Review 9.  Nrf2: The Master and Captain of Beta Cell Fate.

Authors:  Sharon Baumel-Alterzon; Liora S Katz; Gabriel Brill; Adolfo Garcia-Ocaña; Donald K Scott
Journal:  Trends Endocrinol Metab       Date:  2020-11-23       Impact factor: 12.015

10.  Single-cell RNA-sequencing of herpes simplex virus 1-infected cells connects NRF2 activation to an antiviral program.

Authors:  Emanuel Wyler; Vedran Franke; Jennifer Menegatti; Christine Kocks; Anastasiya Boltengagen; Samantha Praktiknjo; Barbara Walch-Rückheim; Jens Bosse; Nikolaus Rajewsky; Friedrich Grässer; Altuna Akalin; Markus Landthaler
Journal:  Nat Commun       Date:  2019-10-25       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.